Abbott Agrees to $385M Settlement Over Infant Formula Plant False Claims
Abbott has reached a $385 million settlement with US authorities over alleged false claims related to infant formula produced at its Michigan facility. The case stems from a 2022 recall and temporary shutdown of the plant amid concerns over bacterial contamination. Despite the settlement, Abbott maintains that no distributed formula tested positive for Cronobacter sakazakii. The company also noted that government testing found no bacteria present in any unopened products from the facility.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.



Discussion (0)
Log in to join the discussion and vote.
Log in